The creator prefers Eli Lilly stock over Novo Nordisk, acknowledging potential bias as they own Eli Lilly stock.
Source Post
Novo Nordisk Stock: Buy or Sell? | NVO Stock Analysis
Aug 10, 2026
Novo Nordisk's stock is down 8% year-to-date, despite significant revenue growth driven by GLP1 products. While future revenue growth is expected to slow, profitability remains high. The creator updated their DCF valuation, lowering free cash flow estimates but still finding the stock undervalued with a fair value of $123.
Linked Mentions
Tickers discussed in this post
Novo Nordisk is still a buying opportunity with a fair value of $123, well above its current market price, despite recent underperformance.
Linked Signals
Tracked calls opened from this post
NVObuy opened Aug 10, 2026
-18.65%